Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eton Pharmaceuticals, Inc.ETON · Entity 4598 | Director · President & CEO | August 19, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eton Pharmaceuticals, Inc.
Report date August 19, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 961,194 |
Ending reported balance
After 2026-08-20 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-19 · Sale · Disposed 8,978 · Balance 1,052,216 F1: The shares were sold in multiple trades at prices ranging from $62.50 to $63.41. The price above reflects the weighted average sales price. F2: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2026-08-20 · Sale · Disposed 47,307 · Balance 1,004,909 F2: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3: The shares were sold in multiple trades at prices ranging from $59.59 to $60.59. The price above reflects the weighted average sales price. Row 3 · 2026-08-20 · Sale · Disposed 36,373 · Balance 968,536 F2: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F4: The shares were sold in multiple trades at prices ranging from $60.61 to $61.61. The price above reflects the weighted average sales price. Row 4 · 2026-08-20 · Sale · Disposed 7,342 · Balance 961,194 F2: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F5: The shares were sold in multiple trades at prices ranging from $61.63 to $62.52. The price above reflects the weighted average sales price. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold in multiple trades at prices ranging from $62.50 to $63.41. The price above reflects the weighted average sales price.
F2: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The shares were sold in multiple trades at prices ranging from $59.59 to $60.59. The price above reflects the weighted average sales price.
F4: The shares were sold in multiple trades at prices ranging from $60.61 to $61.61. The price above reflects the weighted average sales price.
F5: The shares were sold in multiple trades at prices ranging from $61.63 to $62.52. The price above reflects the weighted average sales price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 20, 2026 22:26 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 7,342 | $62.12 | $456,085.04 |
DisclosureSEC source: 0001437749-26-028651 · rdgdoc.xml · nonDerivative · entry 4 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 961,194 F2 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F5 · price: The shares were sold in multiple trades at prices ranging from $61.63 to $62.52. The price above reflects the weighted average sales price. Read SEC document |
| August 20, 2026 Filed Aug 20, 2026 22:26 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 36,373 | $61.11 | $2,222,754.03 |
DisclosureSEC source: 0001437749-26-028651 · rdgdoc.xml · nonDerivative · entry 3 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 968,536 F2 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F4 · price: The shares were sold in multiple trades at prices ranging from $60.61 to $61.61. The price above reflects the weighted average sales price. Read SEC document |
| August 20, 2026 Filed Aug 20, 2026 22:26 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 47,307 | $60.17 | $2,846,462.19 |
DisclosureSEC source: 0001437749-26-028651 · rdgdoc.xml · nonDerivative · entry 2 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,004,909 F2 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · price: The shares were sold in multiple trades at prices ranging from $59.59 to $60.59. The price above reflects the weighted average sales price. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 22:26 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 8,978 | $62.65 | $562,471.70 |
DisclosureSEC source: 0001437749-26-028651 · rdgdoc.xml · nonDerivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,052,216 F1 · price: The shares were sold in multiple trades at prices ranging from $62.50 to $63.41. The price above reflects the weighted average sales price. F2 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 21:01 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantCommon Stock · Derivative | 128,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-025709 · rdgdoc.xml · derivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,985 Underlying: Common Stock · 128,985 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2026, the reporting person was granted 128,985 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. F1 · derivative.exercise_date: On July 31, 2026, the reporting person was granted 128,985 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. F1 · derivative.expiration_date: On July 31, 2026, the reporting person was granted 128,985 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. Read SEC document |
| July 14, 2026 Filed Jul 14, 2026 21:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionEmployee Stock Option · Derivative | 200,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001437749-26-023570 · rdgdoc.xml · derivative · entry 4 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2027-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vested annually from the date of grant (11-10-2017) in four equal installments. Read SEC document |
| July 14, 2026 Filed Jul 14, 2026 21:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionCommon Stock | 200,000 | $1.37 | $274,000.00 |
DisclosureSEC source: 0001437749-26-023570 · rdgdoc.xml · nonDerivative · entry 2 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,061,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2026 Filed Jul 14, 2026 21:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionRestricted Stock Units · Derivative | 27,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-023570 · rdgdoc.xml · derivative · entry 3 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On July 12, 2022, the reporting person was granted 110,000 restricted stock units which vested in four equal installments beginning July 12, 2023. F1 · derivative.expiration_date: On July 12, 2022, the reporting person was granted 110,000 restricted stock units which vested in four equal installments beginning July 12, 2023. Read SEC document |
| July 12, 2026 Filed Jul 14, 2026 21:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionCommon Stock | 27,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-023570 · rdgdoc.xml · nonDerivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 861,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 12, 2022, the reporting person was granted 110,000 restricted stock units which vested in four equal installments beginning July 12, 2023. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:16 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 148 | $32.67 | $4,835.16 |
DisclosureSEC source: 0001437749-26-018879 · rdgdoc.xml · nonDerivative · entry 2 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 833,694 Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:16 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 119,852 | $31.88 | $3,820,881.76 |
DisclosureSEC source: 0001437749-26-018879 · rdgdoc.xml · nonDerivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 833,842 F1 · price: The shares were sold in multiple trades at prices ranging from $31.59 to $32.55. The price above reflects the weighted average sales price. F2 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 23:04 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 100,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-001290 · rdgdoc.xml · derivative · entry 3 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,147,829 Underlying: Common Stock · 100,517 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F6 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F6 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 23:04 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantEmployee Stock Option (Right to Buy) · Derivative | 158,046 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001437749-26-001290 · rdgdoc.xml · derivative · entry 2 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,047,312 Underlying: Common Stock · 158,046 shares Expires 2036-01-11 F4 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030. Read SEC document |
| January 01, 2026 Filed Jan 14, 2026 23:04 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Tax withholdingCommon Stock | 5,015 | $15.39 | $77,180.85 |
DisclosureSEC source: 0001437749-26-001290 · rdgdoc.xml · nonDerivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,889,266 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units. F2 · price: The shares were sold in multiple trades at prices ranging from $15.39 to $15.42. The price reported above reflects the weighted average sales price. F3 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 21:54 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Tax withholdingCommon Stock | 6,732 | $16.83 | $113,299.56 |
DisclosureSEC source: 0001437749-25-037741 · rdgdoc.xml · nonDerivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,894,281 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units. F2 · price: The shares were sold in multiple trades at prices ranging from $16.66 to $16.98. The price reported above reflects the weighted average sales price. F3 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 05, 2025 Filed Jun 5, 2025 21:15 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 70,000 | $16.81 | $1,176,700.00 |
DisclosureSEC source: 0001437749-25-019583 · rdgdoc.xml · nonDerivative · entry 5 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,873,513 F5 · price: The shares were sold in multiple trades at prices ranging from $16.62 to $17.15. The price reported above reflects the weighted average sales price. F6 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 21:15 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 70,000 | $17.00 | $1,190,000.00 |
DisclosureSEC source: 0001437749-25-019583 · rdgdoc.xml · nonDerivative · entry 4 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,943,513 F4 · price: The shares were sold in multiple trades at prices ranging from $16.86 to $17.20. The price reported above reflects the weighted average sales price. F6 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:15 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 400 | $19.02 | $7,608.00 |
DisclosureSEC source: 0001437749-25-019583 · rdgdoc.xml · nonDerivative · entry 3 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,013,513 F3 · price: The shares were sold in multiple trades at a price of $19.02. F6 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:15 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 8,655 | $18.38 | $159,078.90 |
DisclosureSEC source: 0001437749-25-019583 · rdgdoc.xml · nonDerivative · entry 2 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,013,913 F2 · price: The shares were sold in multiple trades at prices ranging from $18.15 to $18.85. The price reported above reflects the weighted average sales price. F6 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:15 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 60,945 | $17.38 | $1,059,224.10 |
DisclosureSEC source: 0001437749-25-019583 · rdgdoc.xml · nonDerivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,022,568 F1 · price: The shares were sold in multiple trades at prices ranging from $17.00 to $17.88. The price reported above reflects the weighted average sales price. F6 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 21:18 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 72,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-000457 · rdgdoc.xml · derivative · entry 2 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,004 Underlying: Common Stock · 72,004 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 3, 2026, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 3, 2026, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 21:18 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantEmployee Stock Option (Right to Buy) · Derivative | 107,469 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001437749-25-000457 · rdgdoc.xml · derivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,469 Underlying: Common Stock · 107,469 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 3, 2029. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:19 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 438,633 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001437749-24-004365 · rdgdoc.xml · derivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,473,014 Underlying: Common Stock · 438,633 shares Expires 2034-02-12 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 13, 2028. Read SEC document |
| March 03, 2023 Filed Mar 3, 2023 21:10 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 350,381 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001493152-23-006671 · ownership.xml · derivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,951,881 Underlying: Common Stock · 350,381 shares Expires 2033-02-19 F1 · date: Option was approved by the Compensation Committee of the Board of Directors as of February 20, 2023 and approved by the full Board of Directors on March 3, 2023. F2 · derivative.exercise_date: The Shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 20, 2027. Read SEC document |
| September 22, 2022 Filed Sep 23, 2022 14:58 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock | 10,000 | $2.10 | $21,042.00 |
DisclosureSEC source: 0001493152-22-026629 · ownership.xml · nonDerivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040,000 Read SEC document |
| July 12, 2022 Filed Jul 18, 2022 20:36 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-019669 · ownership.xml · derivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning July 12, 2023, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning July 12, 2023, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document |
| February 07, 2022 Filed Feb 28, 2022 21:27 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option(Right to buy) · Derivative | 416,500 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001493152-22-005605 · ownership.xml · derivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,601,500 Underlying: Common Stock · 416,500 shares Expires 2032-02-07 F1 · derivative.exercise_date: The shares subject to the option shall vest in 24 equal monthly installments from the date of grant until fully vested and exercisable on February 7, 2024. Read SEC document |
| August 20, 2021 Filed Aug 20, 2021 20:06 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock | 10,000 | $4.32 | $43,200.00 |
DisclosureSEC source: 0001493152-21-020807 · form4.xml · nonDerivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,030,000 Read SEC document |
| June 03, 2021 Filed Jun 3, 2021 16:11 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock | 5,000 | $5.96 | $29,800.00 |
DisclosureSEC source: 0001493152-21-013513 · ownership.xml · nonDerivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,030,000 Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:16 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option(Right to buy) · Derivative | 245,000 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001493152-21-010524 · ownership.xml · derivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,185,000 Underlying: Common Stock · 245,000 shares Expires 2031-05-03 F1 · derivative.exercise_date: The shares subject to the option shall vest in 24 equal monthly installments from the date of grant until fully vested and exercisable on May 3, 2023. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 20:52 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 490,000 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0001493152-20-004052 · ownership.xml · derivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490,000 Underlying: Common Stock · 490,000 shares Expires 2030-03-11 F1 · derivative.exercise_date: The shares subject to the option shall vest in 24 equal monthly installments from the date of grant until fully vested and exercisable on March 12, 2022. Read SEC document |
| August 13, 2019 Filed Aug 13, 2019 20:04 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock | 5,000 | $6.15 | $30,750.00 |
DisclosureSEC source: 0001209191-19-045738 · doc4.xml · nonDerivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025,000 Read SEC document |
| May 21, 2019 Filed May 22, 2019 20:25 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock | 8,600 | $7.96 | $68,431.06 |
DisclosureSEC source: 0001209191-19-032054 · doc4.xml · nonDerivative · entry 2 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,020,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.90 to $8.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| May 20, 2019 Filed May 22, 2019 20:25 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock | 1,400 | $7.78 | $10,894.80 |
DisclosureSEC source: 0001209191-19-032054 · doc4.xml · nonDerivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,400 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.77 to $7.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| February 20, 2019 Filed Mar 8, 2019 21:30 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001209191-19-018103 · doc4.xml · derivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-02-19 F1 · derivative.exercise_date: The shares subject to the option shall vest in 24 equal monthly installments from the date of grant until fully vested and exercisable on February 20, 2021. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 00:23 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | ConversionSeries A Convertible Preferred Stock · Derivative | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-058826 · doc4.xml · derivative · entry 3 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by LLC Disclosed balance after: 0 Underlying: Common Stock · 24,940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock. The shares have no expiration date. F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock. The shares have no expiration date. F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock. The shares have no expiration date. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 00:23 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock | 10,000 | $6.00 | $60,000.00 |
DisclosureSEC source: 0001209191-18-058826 · doc4.xml · nonDerivative · entry 2 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010,000 Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 00:23 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | ConversionCommon Stock | 24,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-058826 · doc4.xml · nonDerivative · entry 1 BRYNJELSEN SEAN · CIK 0001669976 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by LLC Disclosed balance after: 24,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock. The shares have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.